Octreotide and hepatocellular carcinoma.
作者信息
Farinati F, Sergio A, Baldan A, Zucchetta P, Corleto V D
出版信息
Br J Cancer. 2007 Jun 4;96(11):1778-9. doi: 10.1038/sj.bjc.6603799. Epub 2007 May 15.
Abstract
摘要
相似文献
1
Octreotide and hepatocellular carcinoma.
Br J Cancer. 2007 Jun 4;96(11):1778-9. doi: 10.1038/sj.bjc.6603799. Epub 2007 May 15.
2
[Somatostatin analogue (octreotide)].
Nihon Rinsho. 2001 Oct;59 Suppl 6:674-7.
3
[A therapeutic study of hepatocellular carcinoma using octreotide (HECTOR). Hepatocellular Carcinoma: Treatment with Octreotide].
Dtsch Med Wochenschr. 2000 Mar 17;125(11):320.
4
Octreotide treatment of hepatocellular carcinoma.
Hepatology. 2003 Feb;37(2):477. doi: 10.1053/jhep.2003.50026.
5
Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of somatostatin receptors.
J Hepatol. 2004 May;40(5):792-8. doi: 10.1016/j.jhep.2004.01.016.
6
Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.
Eur J Cancer. 2009 Jul;45(10):1788-97. doi: 10.1016/j.ejca.2009.02.018. Epub 2009 Mar 19.
7
The role of somatostatin analogs in the management of hepatocellular carcinoma.
J Endocrinol Invest. 2003;26(8 Suppl):131-3.
8
Antineoplastic mechanism of Octreotide action in human hepatoma.
Chin Med J (Engl). 2001 Nov;114(11):1167-70.
9
Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide.
Br J Cancer. 2006 Oct 9;95(7):853-61. doi: 10.1038/sj.bjc.6603325. Epub 2006 Sep 5.
10
Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations.
Endocr Relat Cancer. 2014;21(6):R485-93. doi: 10.1530/ERC-14-0389. Epub 2014 Oct 21.
引用本文的文献
1
Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets.
BMC Cancer. 2017 Dec 28;17(1):896. doi: 10.1186/s12885-017-3911-3.
本文引用的文献
1
Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.
Hepatology. 2007 Jan;45(1):9-15. doi: 10.1002/hep.21468.
2
Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide.
Br J Cancer. 2006 Oct 9;95(7):853-61. doi: 10.1038/sj.bjc.6603325. Epub 2006 Sep 5.
3
Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma.
J Cancer Res Clin Oncol. 2006 Nov;132(11):699-708. doi: 10.1007/s00432-006-0118-4. Epub 2006 Jul 12.
4
Management of hepatocellular carcinoma.
Hepatology. 2005 Nov;42(5):1208-36. doi: 10.1002/hep.20933.
5
Octreotide therapy for advanced hepatocellular carcinoma.
J Clin Gastroenterol. 2005 Apr;39(4):333-8. doi: 10.1097/01.mcg.0000155136.35315.de.
6
Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma.
Gut. 2004 Aug;53(8):1180-9. doi: 10.1136/gut.2003.036053.
7
Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas.
J Hepatol. 2004 Jul;41(1):112-8. doi: 10.1016/j.jhep.2004.03.018.
8
A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.
Hepatology. 2002 Sep;36(3):687-91. doi: 10.1053/jhep.2002.35071.
9
Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.
Gut. 1998 Mar;42(3):442-7. doi: 10.1136/gut.42.3.442.
Zotero 插件